A scalable solution for isolating human multipotent clinical-grade neural stem cells from ES precursors.
BACKGROUND
A well-characterized method has not yet been established to reproducibly, efficiently, and safely isolate large numbers of clinical-grade multipotent human neural stem cells (hNSCs) from embryonic stem cells (hESCs). Consequently, the transplantation of neurogenic/gliogenic precursors into the CNS for the purpose of cell replacement or neuroprotection in humans with injury or disease has not achieved widespread testing and implementation.


METHODS
Here, we establish an approach for the in vitro isolation of a highly expandable population of hNSCs using the manual selection of neural precursors based on their colony morphology (CoMo-NSC). The purity and NSC properties of established and extensively expanded CoMo-NSC were validated by expression of NSC markers (flow cytometry, mRNA sequencing), lack of pluripotent markers and by their tumorigenic/differentiation profile after in vivo spinal grafting in three different animal models, including (i) immunodeficient rats, (ii) immunosuppressed ALS rats (SOD1G93A), or (iii) spinally injured immunosuppressed minipigs.


RESULTS
In vitro analysis of established CoMo-NSCs showed a consistent expression of NSC markers (Sox1, Sox2, Nestin, CD24) with lack of pluripotent markers (Nanog) and stable karyotype for more than 15 passages. Gene profiling and histology revealed that spinally grafted CoMo-NSCs differentiate into neurons, astrocytes, and oligodendrocytes over a 2-6-month period in vivo without forming neoplastic derivatives or abnormal structures. Moreover, transplanted CoMo-NSCs formed neurons with synaptic contacts and glia in a variety of host environments including immunodeficient rats, immunosuppressed ALS rats (SOD1G93A), or spinally injured minipigs, indicating these cells have favorable safety and differentiation characteristics.


CONCLUSIONS
These data demonstrate that manually selected CoMo-NSCs represent a safe and expandable NSC population which can effectively be used in prospective human clinical cell replacement trials for the treatment of a variety of neurodegenerative disorders, including ALS, stroke, spinal traumatic, or spinal ischemic injury.
['Bohaciakova|Dasa|D|', 'Hruska-Plochan|Marian|M|', 'Tsunemoto|Rachel|R|', 'Gifford|Wesley D|WD|', 'Driscoll|Shawn P|SP|', 'Glenn|Thomas D|TD|', 'Wu|Stephanie|S|', 'Marsala|Silvia|S|', 'Navarro|Michael|M|', 'Tadokoro|Takahiro|T|', 'Juhas|Stefan|S|', 'Juhasova|Jana|J|', 'Platoshyn|Oleksandr|O|', 'Piper|David|D|', 'Sheckler|Vickie|V|', 'Ditsworth|Dara|D|', 'Pfaff|Samuel L|SL|', 'Marsala|Martin|M|']
D002460:Cell Line D005434:Flow Cytometry D006801:Humans D039902:Multipotent Stem Cells D058953:Neural Stem Cells
Amyotrophic lateral sclerosis (ALS) Bioinformatic tools to study xenografts Human embryonic stem cell (hESC) Neural stem cell (NSC) Spinal cord Spinal traumatic injury